...
首页> 外文期刊>Folia histochemica et cytobiologica >Assessment of expression of selected Bcl-2 family proteins in lymphoid infiltration in patients with B-cell chronic lymphocytic leukaemia treated with nucleoside analogues.
【24h】

Assessment of expression of selected Bcl-2 family proteins in lymphoid infiltration in patients with B-cell chronic lymphocytic leukaemia treated with nucleoside analogues.

机译:评估核苷类似物治疗的B细胞慢性淋巴细胞性白血病患者淋巴浸润中所选Bcl-2家族蛋白的表达。

获取原文
获取原文并翻译 | 示例
           

摘要

B-cell chronic lymphocytic leukaemia (B-CLL) is characterized by clonal growth and accumulation of mature lymphoid cells due to disturbance in genetically regulated form of cell death called apoptosis. The intrinsic mechanism of apoptosis is controlled by Bcl-2 family proteins. Purine nucleoside analogues induce the apoptosis in cells in a state of quiescence. The aim of the study was to assess expression of selected Bcl-2 family proteins in neoplastic infiltration in bone marrow in patients with B-CLL treated with nucleoside analogues. The study comprised examination of bone marrow obtained routinely by trephine biopsy from 18 patients with B-CLL diagnosed before administration of purine nucleoside analogues treatment and after its completion. Expression of Bcl-2, Bcl-x and Bax proteins was examined. Lymphoid cells in bone marrow were present in all patients before administration of treatment. After treatment in two patients bone marrow was infiltrated in diffuse pattern, whereas other patients presented nodular pattern of infiltration. The difference between stage of infiltration before and after treatment was statistically significant (p<0.002). High percentage of infiltration cells with positive anti Bcl-2 reaction from 42.0% in one patient to 85.33+/-3.06% in four patients before treatment was observed. After treatment percentage of infiltration cells with positive anti Bcl-2 antibody reaction was from 33.0+/-18.38% in two patients to 99.0% in one patient. Positive correlation between stage of infiltration and expression of Bcl-2 protein was confirmed before and after treatment. Such correlations were not observed in case of Bax and Bcl-x. Strong staining of immunohistochemical reaction of cells in lymphoid infiltration with Bcl-2 antibody was confirmed. There was a difference between Bcl-/Bax ratio before and after treatment. Immunohistochemical assessment of expression of Bcl-2 family proteins in cells of lymphoid infiltration in bone marrow of patients with CLL is an important method in detection of minimal residual disease (MRD) after treatment.
机译:B细胞慢性淋巴细胞性白血病(B-CLL)的特征在于成熟的淋巴细胞的克隆生长和积累,这是由于遗传调控的细胞死亡形式(称为凋亡)受到干扰而引起的。凋亡的内在机制是由Bcl-2家族蛋白控制的。嘌呤核苷类似物以静止状态诱导细胞凋亡。这项研究的目的是评估核苷类似物治疗的B-CLL患者骨髓肿瘤浸润中所选Bcl-2家族蛋白的表达。这项研究包括对18名B-CLL患者(经嘌呤核苷类似物治疗之前和完成治疗后)经环戊活检常规获得的骨髓进行检查。检查了Bcl-2,Bcl-x和Bax蛋白的表达。给予治疗前,所有患者均存在骨髓淋巴样细胞。治疗后,两名患者的骨髓以弥漫性浸润,而其他患者呈结节性浸润。治疗前后浸润阶段之间的差异具有统计学意义(p <0.002)。观察到治疗前,具有高抗Bcl-2反应阳性的浸润细胞百分比从一名患者的42.0%升高至四名患者的85.33 +/- 3.06%。治疗后,具有抗Bcl-2抗体阳性反应的浸润细胞百分比从两名患者的33.0 +/- 18.38%增至一名患者的99.0%。治疗前后证实浸润阶段与Bcl-2蛋白表达呈正相关。在Bax和Bcl-x的情况下未观察到这种相关性。证实了Bcl-2抗体对淋巴样浸润中细胞的免疫组织化学反应进行了强染色。治疗前后Bcl- / Bax比值之间存在差异。免疫组化评估CLL患者骨髓淋巴样浸润细胞中Bcl-2家族蛋白的表达,是检测治疗后微小残留疾病(MRD)的重要方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号